已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

医学 内科学 曲妥珠单抗 临床终点 胃肠病学 免疫组织化学 肿瘤科 癌症 外科 乳腺癌 临床试验
作者
Funda Meric‐Bernstam,Vicky Makker,Ana Oaknin,Do‐Youn Oh,Susana Banerjee,Antonio González‐Martín,Kyung Hae Jung,Iwona Ługowska,Luís Manso,Aránzazu Manzano,Bohuslav Melichar,Salvatore Siena,Daniil Stroyakovskiy,Anitra Fielding,Yan Ma,Soham D. Puvvada,Norah J. Shire,Jung‐Yun Lee
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:42 (1): 47-58 被引量:151
标识
DOI:10.1200/jco.23.02005
摘要

PURPOSE Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non–small-cell lung cancer. Treatments are limited for other HER2-expressing solid tumors. METHODS This open-label phase II study evaluated T-DXd (5.4 mg/kg once every 3 weeks) for HER2-expressing (immunohistochemistry [IHC] 3+/2+ by local or central testing) locally advanced or metastatic disease after ≥1 systemic treatment or without alternative treatments. The primary end point was investigator-assessed confirmed objective response rate (ORR). Secondary end points included safety, duration of response, progression-free survival (PFS), and overall survival (OS). RESULTS At primary analysis, 267 patients received treatment across seven tumor cohorts: endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and other. The median follow-up was 12.75 months. In all patients, the ORR was 37.1% (n = 99; [95% CI, 31.3 to 43.2]), with responses in all cohorts; the median DOR was 11.3 months (95% CI, 9.6 to 17.8); the median PFS was 6.9 months (95% CI, 5.6 to 8.0); and the median OS was 13.4 months (95% CI, 11.9 to 15.5). In patients with central HER2 IHC 3+ expression (n = 75), the ORR was 61.3% (95% CI, 49.4 to 72.4), the median DOR was 22.1 months (95% CI, 9.6 to not reached), the median PFS was 11.9 months (95% CI, 8.2 to 13.0), and the median OS was 21.1 months (95% CI, 15.3 to 29.6). Grade ≥3 drug-related adverse events were observed in 40.8% of patients; 10.5% experienced adjudicated drug-related interstitial lung disease (ILD), with three deaths. CONCLUSION Our study demonstrates durable clinical benefit, meaningful survival outcomes, and safety consistent with the known profile (including ILD) in pretreated patients with HER2-expressing tumors receiving T-DXd. Greatest benefit was observed for the IHC 3+ population. These data support the potential role of T-DXd as a tumor-agnostic therapy for patients with HER2-expressing solid tumors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
勤奋迎天完成签到,获得积分10
1秒前
2秒前
sunboy14521完成签到 ,获得积分10
2秒前
一秋一年发布了新的文献求助10
2秒前
HYT完成签到 ,获得积分10
4秒前
NexusExplorer应助仁爱的平彤采纳,获得10
4秒前
6秒前
Orange应助齐小明采纳,获得10
7秒前
Singularity应助娜扎采纳,获得10
8秒前
DHL完成签到,获得积分10
9秒前
9秒前
wangfeng007发布了新的文献求助10
10秒前
牟翎发布了新的文献求助20
12秒前
潘丝洞完成签到,获得积分10
13秒前
松门紫藤发布了新的文献求助20
17秒前
科研通AI2S应助ruru采纳,获得10
17秒前
Owen应助carbonell采纳,获得10
17秒前
juziyaya应助charles采纳,获得10
20秒前
顾矜应助刘星星采纳,获得10
21秒前
Dr.完成签到 ,获得积分10
22秒前
24秒前
25秒前
28秒前
豆豆发布了新的文献求助10
29秒前
30秒前
刘星星发布了新的文献求助10
34秒前
传奇3应助沉默安波采纳,获得10
34秒前
Singularity应助lu采纳,获得10
36秒前
38秒前
39秒前
123应助流星采纳,获得10
40秒前
李白发布了新的文献求助30
41秒前
41秒前
42秒前
娜扎给娜扎的求助进行了留言
43秒前
贾jia发布了新的文献求助30
43秒前
进击的阿木木完成签到,获得积分10
43秒前
精明一寡发布了新的文献求助10
46秒前
46秒前
huanhuan完成签到 ,获得积分10
46秒前
高分求助中
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
宽禁带半导体紫外光电探测器 388
COSMETIC DERMATOLOGY & SKINCARE PRACTICE 388
Pearson Edxecel IGCSE English Language B 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3142320
求助须知:如何正确求助?哪些是违规求助? 2793260
关于积分的说明 7806108
捐赠科研通 2449516
什么是DOI,文献DOI怎么找? 1303345
科研通“疑难数据库(出版商)”最低求助积分说明 626823
版权声明 601300